Interim phase 3 results showed the IL-13 monoclonal antibody improves histology and symptoms in EoE, even in participants ...

Highlights:,Merck & Co Inc's experimental treatment, clesrovimab, has demonstrated positive results in a mid- to late-stage ...

Controlled release drug delivery market. Global Controlled Release Drug Delivery market Outlook 2024-2032: Rising Demand and Key Trends: Controlled release ...

Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind of the Covid pandemic, propelling the stock to an all-time high in 2021. Since then, the shares have tumbled ...

We recently compiled a list of the 7 Blue Chip Stocks with Low PE Ratios. In this article, we are going to take a look at ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

The global veterinary biologics market is on a robust growth trajectory, with its valuation expected to reach USD 13,140.6 ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...